Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Genomic Biomarkers Market Growth From $10.24 Billion In 2026 To $19.32 Billion By 2030 At A CAGR Of 17.2%

The market for genomic biomarkers has experienced substantial expansion, projecting a rise from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate of 17.5%. This growth trajectory is underpinned by key factors observed during the earlier period, including significant progress in genomic sequencing techniques, a broader focus on biomarker research within oncology, the escalating use of tailored therapeutic strategies, enhancements in the structures for clinical validation, and the increasing accessibility of genomic data repositories.

The genomic biomarkers market is projected for swift expansion in the upcoming years. Anticipated to reach $19.33 billion by 2030, this growth trajectory reflects a compound annual growth rate (CAGR) of 17.2%. Multiple factors are expected to fuel this increase during the forecast period, including augmented funding for precision medicine initiatives, a heightened need for diagnostic tools enabling earlier disease identification, the broadening scope of drug development reliant on biomarkers, greater incorporation of artificial intelligence into genomic analysis, and escalating regulatory endorsement of individualized treatment approaches. Key developments anticipated within this timeframe involve a surge in the application of biomarker-directed precision medicine, increased utilization of genomic information in guiding clinical choices, a more prevalent use of companion diagnostics, the proliferation of multi-omics platforms for biomarker discovery, and a stronger emphasis on establishing robust clinical validation standards.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

Genomic Biomarkers Market Growth Factors: Which Forces Are Supporting Market Expansion?

The elevated need for healthcare tailored to individual patients, referred to as personalized or precision medicine, is poised to be a significant driver for the expansion of the genomic biomarkers market. This tailored medical strategy leverages an individual’s genetic and genomic profile to inform healthcare choices and treatment plans. Key contributors to this rising demand include a greater focus on patient-centered healthcare, continuous advancements in genetic sequencing and analysis technologies, and the integration of Electronic Health Records for robust data management and interpretation. Genomic biomarkers are instrumental in this paradigm, empowering clinicians to customize therapies based on a patient’s specific genetic composition, thereby enhancing treatment efficacy and mitigating adverse reactions. A notable illustration of this trend is the U.S. Food and Drug Administration’s approval of 16 new personalized treatments for rare disease patients in 2023, a substantial increase from the six approvals in 2022, as highlighted by the Personalized Medicine Coalition in February 2024. Consequently, the growing imperative for personalized medicine directly fuels the growth trajectory of the genomic biomarkers market.

Genomic Biomarkers Market Segments: Where Are The Largest Growth Opportunities?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Genomic Biomarkers Market Industry Trends: What Changes Are Reshaping Demand?

Key players within the genomic biomarkers sector are concentrating their efforts on the creation of novel offerings, such as reagents for lung cancer diagnostics, aimed at refining the identification of particular genetic anomalies, boosting the precision of diagnoses, and enabling tailored therapeutic strategies through the application of cutting-edge genomic techniques. These specialized lung reagents, which are chemical or biological agents crucial for diagnostic assays, investigative studies, or therapeutic interventions concerning the lungs, play a vital role in advancing precision medicine by informing treatment decisions based on an individual’s unique cancer genetic makeup. As an illustration, in December 2023, Biofidelity, a United Kingdom enterprise dedicated to the advancement of sophisticated genomic testing and diagnostic accuracy, introduced its ASPYRE-Lung reagents. The purpose of the ASPYRE-Lung reagents is to pinpoint significant genetic mutations and changes within lung cancer, which are instrumental in directing the selection of targeted treatments and personalized care plans.

Genomic Biomarkers Market Major Participants And Competitive Dynamics

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Access The Complete Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Genomic Biomarkers Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the genomic biomarkers market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model